Avecho Biotechnology Hosts Investor Webinar Amidst Key Licensing Agreement and Clinical Trial Progress

An announcement from Avecho Biotechnology Limited ( (AU:AVE) ) is now available.

Avecho Biotechnology Limited has announced an investor webinar following its licensing agreement with Sandoz Group AG. The company is conducting a pivotal Phase III trial of its CBD TPM soft-gel capsules aimed at reducing insomnia severity, with the trial being the largest of its kind in Australia. This development is significant as it positions Avecho to potentially be the first to market with an over-the-counter CBD product for insomnia in Australia, tapping into a growing market projected to exceed US$125 million annually.

More about Avecho Biotechnology Limited

Avecho Biotechnology Limited is a company that develops and commercializes innovative human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM). This system enhances the solubility and absorption of drugs and nutrients. Avecho’s lead product is a cannabidiol (CBD) TPM soft-gel capsule, which is currently in Phase III clinical development for treating insomnia.

Current Market Cap: A$22.19M

For an in-depth examination of AVE stock, go to TipRanks’ Stock Analysis page.